Form 8-K - Current report:
SEC Accession No. 0001601485-24-000057
Filing Date
2024-10-17
Accepted
2024-10-17 08:31:53
Documents
13
Period of Report
2024-10-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K angn-20241015.htm   iXBRL 8-K 23434
  Complete submission text file 0001601485-24-000057.txt   152601

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT angn-20241015.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT angn-20241015_lab.xml EX-101.LAB 22786
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT angn-20241015_pre.xml EX-101.PRE 13130
16 EXTRACTED XBRL INSTANCE DOCUMENT angn-20241015_htm.xml XML 2907
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 241375960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)